While some teenagers may puff on cigarettes to ’self-medicate’ against the blues, scientists at the University of Toronto and the University of Montreal have found that smoking may actually increase depressive symptoms in some adolescents. Published in the journal Addictive Behaviors, the findings are part of the long-term Nicotine Dependence in Teens (NDIT) study based at the University of Montreal Hospital Research Centre.
The rest is here:
Smoking increases depressive symptoms in teens
(PhysOrg.com) — The world could one day be an economically equal place, if the lower-income population have anything to do with it. In an interesting yet disheartening series of socioeconomic experiments, led by a team of UC Berkeley researchers, the findings are that those on the lower-income levels are more likely to give and be charitable than their higher paid counterparts.
Read the original here:
The rich have more money but the poor are rich in heart: study
A new infectious disease spreading rapidly across the northeastern United States has killed millions of bats and is predicted to cause regional extinction of a once-common bat species, according to the findings of a University of California, Santa Cruz researcher.
Read more from the original source:
Bats facing regional extinction from rapidly spreading disease
When published results are systematically tracked for drug trials registered with ClinicalTrials.gov, those from industry-funded trials are the likeliest to be favorable to the drug in question, report researchers at Children’s Hospital Boston. Publishing in the August 3 issue of the Annals of Internal Medicine, the researchers call for more public disclosure about clinical drug trials at their outset to reduce the possibility of bias in the findings.
Here is the original post:
Drug trials funded by industry are more likely to publish favorable results
The new drug olaparib has antitumour activity in carriers of the BRCA1 or BRCA2 gene mutations who have advanced ovarian or breast cancer, according to the findings of two proof-of-concept trials. Together with previous findings, these trials suggest that therapy for ovarian, breast, and possibly other cancers can be targeted on the basis of shared genetic defects, rather than organ of origin, conclude the Articles published online in the Lancet.
See the original post here:
Revolutionary therapy slows tumor growth in advanced breast cancer
The firestorm that followed the November 2009 release of guidelines that would have reduced use of screening mammograms in women aged 40 to 49 highlights challenges for implementing the findings of comparative effectiveness research (CER), according to a new analysis. Meeting such challenges — which may become more common due to increased funding for CER — requires better communication to the public and stakeholders about evidence and its connection to health care quality and efficiency, experts say.
See the rest here:
Implementing comparative effectiveness research: Lessons from the mammography screening controversy
A team of researchers from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have defined for the first time the mechanism behind three cancer-causing genes in acute lymphoblastic leukemia. Published in the journal Genes and Development, the findings offer insight on the complex interaction between the genes and their contributions to leukemia, thereby providing the foundation for the design of targeted therapies.
Read the rest here:
Montreal researchers shed light on common juvenile cancer
Kidney cancer is a radiographic diagnosis which means treatment decisions are often made based on the findings of a solid mass on CT or MRI. Unfortunately these tests cannot distinguish the different types of kidney cancers which have variable risks
Read more from the original source:
New tool for pre-surgical detection of kidney cancers may help patients avoid unnecessary surgeries
Nearly three-quarters of Americans are confident in our system for reviewing the effectiveness and safety of new medicines and medical devices, yet 41% say it takes too long to approve a drug and allow it to be sold to consumers. These are among the findings in a new poll from Research!America.
Read the original here:
Poll finds concerns about pace of medical and health research